Select Page

CollPlant to develop 3D bioprinted lung transplants with United Therapeutics

Written by Paul

October 23, 2018

CollPlant , an Israeli 3D bioprinting company and United Therapeutics Corporation , a Maryland-based biotechnology company, have commenced a license, development and commercialization agreement for the development of 3D bioprinted lung transplants. Within this agreement, CollPlant will receive $5 million upfront, as well as regulatory and operational milestone payments of up to $15 million to manufacture and supply its bio-ink to United’s organ-manufacturing and transplantation subsidiary, Lung Biotechnology PBC . CollPlant’s proprietary recombinant human collagen (rhCollagen) is grown and harvested from tobacco plants engineered with five human genes. This purified collagen is used as a foundation when 3D bioprinting solid-organ scaffolds. Professor Oded Shoseyov, CollPlant Founder and Chief Scientific Officer. Photo by Michael Petch. 3D bioprinted lung transplants According to CollPlant, collagen is a primary building block for the human body and has been a vital protein in the medical field as it is essential for tissue repair. Currently, […]


Submit a Comment

Your email address will not be published. Required fields are marked *

You May Also Like…

Pin It on Pinterest

Share This

Share this post with your friends!